IE
TTRX

Israel Englander’s Turn Therapeutics TTRX Stock Holding History

Israel Englander’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Sell
60,551
-9,206
-13% -$42.8K ﹤0.01% 4873
2026
Q1 		$223K Sell
69,757
-25,866
-27% -$101K ﹤0.01% 5136
2025
Q4 		$377K Buy
+95,623
New +$399K ﹤0.01% 5122

Other funds holding TTRX

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BA
Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Israel Englander's TTRX Position: Q2 2026 in Review

Israel Englander reduced its Turn Therapeutics (TTRX) stake by 13% in Q2 2026, selling an estimated $42.8K and leaving 60,551 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #4873.

Israel Englander first reported a position in TTRX in Q4 2025 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

  • Israel Englander held 60,551 shares of Turn Therapeutics worth $442K as of Q2 2026.
  • Israel Englander sold 9,206 Turn Therapeutics shares in Q2 2026, an estimated $42.8K.
  • Turn Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4873 holding.
  • Israel Englander first reported a position in Turn Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.